Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Complement lectin pathway activation is associated with COVID-19 disease severity, independent of MBL2 genotype subgroups.
Hurler L, Szilágyi Á, Mescia F, Bergamaschi L, Mező B, Sinkovits G, Réti M, Müller V, Iványi Z, Gál J, Gopcsa L, Reményi P, Szathmáry B, Lakatos B, Szlávik J, Bobek I, Prohászka ZZ, Förhécz Z, Csuka D, Kajdácsi E, Cervenak L, Kiszel P, Masszi T, Vályi-Nagy I, Würzner R; Cambridge Institute of Therapeutic Immunology and Infectious Disease-National Institute of Health Research (CITIID-NIHR) COVID BioResource Collaboration; Lyons PA, Toonen EJM, Prohászka Z. Hurler L, et al. Among authors: remenyi p. Front Immunol. 2023 Mar 27;14:1162171. doi: 10.3389/fimmu.2023.1162171. eCollection 2023. Front Immunol. 2023. PMID: 37051252 Free PMC article.
Prognostic factors impacting post-transplant outcomes in adult T-cell acute lymphoblastic leukemia: a registry-based study by the EBMT acute leukemia working party.
El Cheikh J, Ngoya M, Galimard JE, Reményi P, Kulagin A, Aljurf M, Mousavi A, Wu D, Ozcelik T, Salmenniemi U, Castilla-Llorente C, Socie G, Helbig G, Schroeder T, Sakellari I, Rambaldi A, Burt R, Busca A, Balsat M, Stelljes M, Brissot E, Giebel S, Peric Z, Nagler A, Bazarbachi A, Ciceri F, Mohty M. El Cheikh J, et al. Among authors: remenyi p. Bone Marrow Transplant. 2024 Sep;59(9):1239-1246. doi: 10.1038/s41409-024-02300-8. Epub 2024 Jun 4. Bone Marrow Transplant. 2024. PMID: 38834689
IgD Subtype But Not IgM or Non-Secretory Is a Prognostic Marker for Poor Survival Following Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Results From the EBMT CALM (Collaboration to Collect Autologous Transplant Outcomes in Lymphomas and Myeloma) Study.
Lawless S, Sbianchi G, Morris C, Iacobelli S, Bosman P, Blaise D, Reményi P, Byrne JL, Mayer J, Apperley J, Lund J, Kobbe G, Schaap N, Isaksson C, Lenhoff S, Basak G, Touzeau C, Wilson KMO, González Muñiz S, Scheid C, Browne P, Anagnostopoulos A, Rambaldi A, Jantunen E, Kröger N, Schönland S, Yakoub-Agha I, Garderet L. Lawless S, et al. Among authors: remenyi p. Clin Lymphoma Myeloma Leuk. 2021 Oct;21(10):686-693. doi: 10.1016/j.clml.2021.05.012. Epub 2021 May 24. Clin Lymphoma Myeloma Leuk. 2021. PMID: 34158265
Should anti-thymocyte globulin be added in post-transplant cyclophosphamide based matched unrelated donor peripheral blood stem cell transplantation for acute myeloid leukemia? A study on behalf of the Acute Leukemia Working Party of the EBMT.
Spyridonidis A, Labopin M, Brissot E, Moiseev I, Cornelissen J, Choi G, Ciceri F, Vydra J, Reményi P, Rovira M, Meijer E, Labussière-Wallet H, Blaise D, van Gorkom G, Kröger N, Koc Y, Giebel S, Bazarbachi A, Savani B, Nagler A, Mohty M. Spyridonidis A, et al. Among authors: remenyi p. Bone Marrow Transplant. 2022 Dec;57(12):1774-1780. doi: 10.1038/s41409-022-01816-1. Epub 2022 Sep 7. Bone Marrow Transplant. 2022. PMID: 36071114
EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL).
Wiktor-Jedrzejczak W, Drozd-Sokolowska J, Eikema DJ, Hoek J, Potter M, Wulf G, Sellner L, Ljungman P, Chevallier P, Volin L, Koc Y, Martin S, Bunjes D, Rovira M, Itälä-Remes M, Foá R, Deconinck E, Gedde-Dahl T, Cornelissen J, Collin M, Brecht A, Patel A, de Groot M, Reményi P, Nagler A, Finke J, Turlure P, Iacobelli S, van Biezen A, Schetelig J, Kröger N, Dreger P. Wiktor-Jedrzejczak W, et al. Among authors: remenyi p. Bone Marrow Transplant. 2019 Sep;54(9):1391-1398. doi: 10.1038/s41409-019-0448-x. Epub 2019 Jan 21. Bone Marrow Transplant. 2019. PMID: 30664723 Clinical Trial.
Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT.
Sanz J, Labopin M, Choi G, Kulagin A, Peccatori J, Vydra J, Reményi P, Versluis J, Rovira M, Blaise D, Labussière-Wallet H, Montoro J, Sica S, Meijer E, Itälä-Remes M, Schaap N, Bulabois CE, Piemontese S, Mohty M, Ciceri F. Sanz J, et al. Among authors: remenyi p. Blood. 2024 Jun 13;143(24):2534-2543. doi: 10.1182/blood.2023023697. Blood. 2024. PMID: 38657278
Improved Posttransplant Outcomes in Recent Years for AML Patients with FLT3-ITD and Wild-type NPM1: A Report from the EBMT Acute Leukemia Working Party.
Bazarbachi A, Labopin M, Gedde-Dahl T, Remenyi P, Forcade E, Kröger N, Socié G, Craddock C, Bourhis JH, Versluis J, Yakoub-Agha I, Salmenniemi U, El-Cheikh J, Bug G, Esteve J, Nagler A, Ciceri F, Mohty M. Bazarbachi A, et al. Among authors: remenyi p. Clin Cancer Res. 2023 Nov 1;29(21):4441-4448. doi: 10.1158/1078-0432.CCR-23-0954. Clin Cancer Res. 2023. PMID: 37603683
Fludarabine-treosulfan versus fludarabine-melphalan or busulfan-cyclophosphamide conditioning in older AML or MDS patients - A clinical trial to registry data comparison.
Beelen DW, Iacobelli S, Koster L, Eikema DJ, van Biezen A, Stölzel F, Ciceri F, Bethge W, Dreger P, Wagner-Drouet EM, Reményi P, Stelljes M, Markiewicz M, McLornan DP, Yakoub-Agha I, Mohty M. Beelen DW, et al. Among authors: remenyi p. Bone Marrow Transplant. 2024 May;59(5):670-679. doi: 10.1038/s41409-024-02241-2. Epub 2024 Feb 21. Bone Marrow Transplant. 2024. PMID: 38383713 Free PMC article. Clinical Trial.
109 results